ab-106 + rifampicin

ab-106 + rifampicin is a combination of two drugs: ab-106 (also known as taletrectinib) and rifampicin. ab-106 (taletrectinib) is a small molecule, next-generation, orally available selective inhibitor of the receptor tyrosine kinases ROS1 and neurotrophic tyrosine receptor kinases (NTRK1, NTRK2, NTRK3), used for the treatment of cancers (notably, advanced non-small cell lung cancer with ROS1 fusion gene and NTRK fusion-positive solid tumors)[2][3][4][5][6]. Rifampicin is a well-known antibiotic of the rifamycin class, primarily used as a broad-spectrum antibacterial agent especially against mycobacteria (notably tuberculosis). There is no evidence for a uniquely branded or separately approved combination product of ab-106 + rifampicin; this must be considered a combination therapy, likely used for pharmacokinetic or drug-drug interaction studies. ab-106 targets oncogenic fusion kinases, disrupting cell proliferation and survival signaling in fusion-driven tumors[2][3][4][6]. Rifampicin acts by inhibiting bacterial DNA-dependent RNA polymerase, suppressing bacterial RNA synthesis. ab-106 is developed for oncology indications, and rifampicin is widely manufactured as an antibiotic.

Brand names

ibtrozi

Other names

taletrectinibab-106 + rifampicin